Merck has reached an agreement with Dr. Falk Pharma to discontinue an existing contract concerning co-development and co-commercialization rights in certain territories for MK-8690.
Magnet Biomedicine, a biopharmaceutical company, has appointed Bharat Reddy, Ph.D., as its new Chief Business Officer.
Boehringer Ingelheim and CDR-Life have announced a new global licensing agreement to develop CDR-Life’s CDR111 for autoimmune diseases.
Strategic financing will advance development of sac-TMT while Merck continues to progress its expansive pipeline.
Kaigene Inc. has entered into an exclusive global licensing agreement with Celltrion Inc. for two of Kaigene's nonclinical-stage assets, KG006 and KG002.